DUBAI (HRNW) An experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) has 86% efficacy, the health ministry of the United Arab Emirates said on Wednesday, citing an interim analysis of late-stage clinical trials.
In July, the Gulf Arab state started Phase III clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG).
In September, it authorised emergency use of the vaccine for certain groups, the first such international clearance for a vaccine developed in China.
The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.
Be the first to comment on "UAE says Sinopharm vaccine has 86% efficacy against COVID-19"